| |
| |
| Exchange: |
N/A |
| Security
Type: |
Common |
| Shares
Out: |
56,296,000 |
| Market
Cap: |
221.24(M) |
| Last
Volume: |
0 |
Avg
Vol: |
0 |
| 52
Week Range: |
$2.07 - $5.88 |
|
| Level
I Sector: |
N/A |
| Level
II Sector: |
N/A |
| Level
III Sector: |
N/A |
|
Member Indexes:
|
Rankings:
|
|
| Insider 3 Months : - |
| Insider 6 Months : - |
| Insider 3/6 Months : - |
|
| Guru Rank Number : - |
| Guru Rank Value : - |
| Guru Occurances : - |
|
|
|
|
|
| |
|
Company Profile Sutro Biopharma is a clinical stage drug discovery, development and manufacturing company focused on deploying its proprietary integrated cell-free protein synthesis platform, XpressCF™, to create a variety of protein therapeutics initially for cancer and autoimmune disorders. Co.'s two product candidates are wholly owned: STRO-001, an antibody-drug conjugates (ADC) directed against CD74, for patients with multiple myeloma and non-Hodgkin lymphoma; and STRO-002, an ADC directed against folate receptor-alpha for patients with ovarian and endometrial cancers.
|
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
|
3m +/-:
|
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
|
Actions:
|
|
|
| B |
Buy |
| S |
Sell |
| OE |
Option
Exercised |
| A |
Acquired |
| D |
Disposed |
| AB |
Automatic
Buy |
| AS |
Automatic
Sell |
| IO |
Initial
Ownership |
|
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
| |
| |
Summary (Direct Transactions Only)  |
3 Months |
6 Months |
12 Months |
24 Months |
| Total Shares Bought |
0 |
0 |
0 |
0 |
| Total Buy Value |
$0 |
$0 |
$0 |
$0 |
| Total People Bought |
0 |
0 |
0 |
0 |
| Total Buy Transactions |
0 |
0 |
0 |
0 |
| Total Shares Sold |
0 |
12,185 |
39,226 |
39,226 |
| Total Sell Value |
$0 |
$60,925 |
$186,802 |
$186,802 |
| Total People Sold |
0 |
1 |
2 |
2 |
| Total Sell Transactions |
0 |
1 |
3 |
3 |
| End Date |
2024-02-15 |
2023-11-14 |
2023-05-16 |
2022-05-16 |
|
| Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
| 3m +/- |
|
|
Form |
  Petree Daniel H |
Director |
– • – |
2019-09-06 |
4 |
OE |
$5.09 |
$4,204 |
D/D |
826 |
3,856 |
|
- |
|
| Fitzpatrick Linda A |
Chief People & Comm. Officer |
• – – |
2019-08-29 |
4 |
OE |
$5.09 |
$4,204 |
D/D |
826 |
826 |
|
- |
|
| Petree Daniel H |
Director |
– • – |
2019-02-12 |
4 |
OE |
$5.09 |
$15,423 |
D/D |
3,030 |
3,030 |
|
- |
|
| Kaneko Yasunori |
10% Owner |
– – • |
2018-10-01 |
4 |
A |
$0.00 |
$0 |
I/I |
1,960,053 |
1,960,053 |
|
- |
|
| Merck Sharp & Dohme Corp. |
10% Owner |
– – • |
2018-10-01 |
4 |
B |
$15.00 |
$9,999,990 |
I/I |
666,666 |
2,723,509 |
1.5 |
- |
|
| Merck Sharp & Dohme Corp. |
10% Owner |
– – • |
2018-10-01 |
4 |
A |
$0.00 |
$0 |
I/I |
2,056,843 |
2,056,843 |
|
- |
|
| Celgene Corp /de/ |
|
– – • |
2018-10-01 |
4 |
A |
$0.00 |
$0 |
D/D |
1,726,197 |
1,726,197 |
|
- |
|
| Hallam Trevor |
Chief Science Officer |
• – – |
2018-10-01 |
4 |
A |
$0.00 |
$0 |
D/D |
2,026 |
15,800 |
|
- |
|
| Janney Daniel |
Director |
– • • |
2018-10-01 |
4 |
A |
$0.00 |
$0 |
I/I |
1,944,901 |
1,944,901 |
|
- |
|
| Petree Daniel H |
Director |
– • – |
2018-10-01 |
4 |
S |
$15.00 |
$1,830 |
I/I |
(122) |
192 |
|
- |
|
| Petree Daniel H |
Director |
– • – |
2018-10-01 |
4 |
OE |
$5.81 |
$1,824 |
I/I |
314 |
314 |
|
- |
|
| Fitzpatrick Linda A |
Chief People & Comm. Officer |
• – – |
2018-10-01 |
4 |
A |
$0.00 |
$0 |
I/I |
10,383 |
10,383 |
|
- |
|
| Newell William J |
CEO & President |
• • – |
2018-10-01 |
4 |
A |
$0.00 |
$0 |
I/I |
2,890 |
21,154 |
|
- |
|
| Newell William J |
CEO & President |
• • – |
2018-10-01 |
4 |
A |
$0.00 |
$0 |
D/D |
9,846 |
188,170 |
|
- |
|
| Freund John Gordon |
Director |
– • • |
2018-10-01 |
4 |
A |
$0.00 |
$0 |
I/I |
1,960,053 |
1,960,053 |
|
- |
|
| Ross Michael Jay |
Director |
– • • |
2018-10-01 |
4 |
A |
$0.00 |
$0 |
I/I |
1,824,542 |
18,248 |
|
- |
|
| Sv Life Sciences Fund V Strategic Partners, L.p. |
10% Owner |
– – • |
2018-10-01 |
4 |
A |
$0.00 |
$0 |
I/I |
1,824,542 |
18,248 |
|
- |
|
| Albini Edward C |
CFO and Secretary |
• – – |
2018-10-01 |
4 |
A |
$0.00 |
$0 |
D/D |
1,688 |
1,688 |
|
- |
|
| Nohra Guy P |
10% Owner |
– – • |
2018-10-01 |
4 |
A |
$0.00 |
$0 |
D/D |
1,944,901 |
1,944,901 |
|
- |
|
219 Records found
|
|
Page 9 of 9 |
|
|
0.41 (9.45%) 
